Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
BioBlast®
Biosimilars Deals 2023
Diversity
Masterclasses
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Patents
PipCast®
PTE
Trade Marks
Webinars

Novo Nordisk Settles with Two Clinics Selling Ozempic and Wegovy Knock-Offs

Feb 5, 2024

Novo Nordisk settled two lawsuits over counterfeit versions of Ozempic® (semaglutide biosimilar) and Wegovy® (semaglutide).  The two companies involved, Cosmetic Laser Professionals Med Spa and Nuvida RxWeight Loss are permanently banned from claiming that their products are approved by the FDA and from using any Novo Nordisk logos or trademarks. 

This news follows the release on 31 January 2024 by Novo Nordisk of its 2023 Annual Report, where it presented an increase in sales by 31% to DKK 232.3B in 2023, representing an increase in its operating profit by 37%.